Saint herblain (France), September 252023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States Department of Defense (DoD). ) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®.
Under this new one-year contract, the Department of Defense will purchase IXIARO for a minimum value of $32 million.® vaccines and has the possibility of acquiring additional doses during the next twelve months. Deliveries will begin immediately.
Dipal PatelBoss Commercial Official by Valneva commented: “We are excited to continue our long-term relationship with the Department of Defense. The US military has trusted IXIARO® for more than ten years to help protect military personnel, their families, civilian government services personnel, and government contractors from this potentially deadly disease.”
IXIARO® is the only JE vaccine approved by the US Food and Drug Administration (FDA) and was developed through a cooperative research and development agreement with the Walter Reed Army Research Institute. In the US, Valneva markets and distributes IXIARO® directly to the military and private travel market.
Valneva Japanese Encephalitis Vaccine is indicated for active immunization for the prevention of the disease in persons traveling or living in endemic areas. It has received marketing approval in the US, Europe, Canada, Hong Kong, Singapore and Israel under the trade name IXIARO.® and in Australia and New Zealand where it is marketed as JESPECT®. It is the only vaccine available to the US military for Japanese encephalitis. IXIARO® is approved for use in people two months of age and older in the US and EU member states, Canada, Norway, Liechtenstein, Iceland, Singapore, Hong Kong, Japan, the Republic of Korea, and Israel. In all other licensed territories, IXIARO®/SPECT® It is indicated for use in people 18 years of age or older.
About Japanese encephalitis
Japanese encephalitis is a deadly infectious disease found primarily in Asia. It is estimated that around 70,000 cases of JE occur in Asia each year, although the actual number of cases is likely to be much higher due to underreporting in rural areas. JE is fatal in about 30 percent of those who show symptoms and leaves half of survivors with permanent brain damage. The disease is endemic in Southeast Asia, India and China, a region with a population of more than three billion. In 2005, JE killed more than 1,200 children in just one month during an epidemic outbreak in Uttar Pradesh, India and Nepal.
About Valneva SE
We are a specialty vaccine company focused on the development, manufacturing and marketing of prophylactic vaccines for infectious diseases. We take a highly specialized and targeted approach to vaccine development, focusing on vaccine solutions that address unmet medical needs to ensure we can make a difference in people’s lives. We apply our deep knowledge of vaccine science, including our expertise in multiple vaccine modalities and our established vaccine development capabilities, to develop vaccines against diseases that cannot yet be prevented by vaccines or for which effective treatment options exist. limited. Today, we are leveraging our experience and capabilities to rapidly advance a broad range of vaccines into and through the clinic, including candidates against chikungunya virus and Lyme disease.
|Contacts with investors and Valneva media
Vice President of Global Communications and European Investor Relations
+33 (0)6 4516 7099
Joshua Drumm, Ph.D.
This press release contains certain forward-looking statements relating to Valneva’s business, including with respect to possible additional orders from IXIARO.®. Furthermore, even if Valneva’s actual results or developments are consistent with the forward-looking statements contained in this press release, those Valneva results or developments may not be indicative of its future. In some cases, you can identify forward-looking statements by words such as “may,” “should,” “could,” “expect,” “anticipate,” “believe,” “intend,” “estimate,” “target,” “objective.” ” or similar words. These forward-looking statements are based largely on Valneva’s current expectations as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause the results, actual performance or achievements may be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In particular, Valneva’s expectations could be affected by, among other things, the changing needs of the U.S. military, uncertainties related to vaccine development and manufacturing, unexpected results of clinical trials, unexpected regulatory actions or delays, competition in general, currency fluctuations. , the impact of the global and European credit crisis, and the ability to obtain or maintain patents or other intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will come true. Valneva provides the information contained in these materials as of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.